Inhibitory effects of hydroxysafflor yellow A on the formation of advanced glycation end products in vitro

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 2050-2053

  Ni, Zhenzhen ^a   Zhuge, Zhengbing ^b   Li, Wenlu ^a   Xu, Huimin ^a   Zhang, Zhongmiao ^a   Dai, Haibin ^a,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Advanced glycation end product; Glycation; Hydroxysafflor yellow A; Inhibitor of glycation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; DODECYL SULFATE SODIUM; HYDROXYSAFFLOR YELLOW A; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SYNTHESIS; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CROSS LINKING; PROTEIN MODIFICATION; SAFFLOWER;

CHALCONE; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; LYSINE; PEPTIDES; PYRUVALDEHYDE; QUINONES; RIBOSE; SERUM ALBUMIN, BOVINE;

EID: 84869219600     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00249     Document Type: Article

References (28)

1. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv. Pharmacol., 23, 1-34 (1992).
2. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. U.S.A., 90, 6434-6438 (1993).
3. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi SN. N(epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry, 35, 8075-8083 (1996).
4. Nagaraj RH, Shipanova IN, Faust FM. Protein cross-linking by the Maillard reaction. Isolation, characterization, and in vivo detection of a lysine-lysine cross-link derived from methylglyoxal. J. Biol. Chem., 271, 19338-19345 (1996).
5. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res. Clin. Pract., 67, 3-21 (2005).
6. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging, 32, 763-777 (2011).
7. Münch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids, 42, 1221-1236 (2012).
8. Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr. Pharm. Des., 14, 946-952 (2008).
9. Stirban A. The role of AGEs and ROS in atherosclerosis. Herz, 35, 170-180 (2010).
10. Baynes JW. The role of AGEs in aging: causation or correlation. Exp. Gerontol., 36, 1527-1537 (2001).
11. Kim JH, Hong CO, Koo YC, Choi HD, Lee KW. Anti-glycation effect of gold nanoparticles on collagen. Biol. Pharm. Bull., 35, 260-264 (2012).
12. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes, 41, 552-556 (1992).
13. Figarola JL, Scott S, Loera S, Xi B, Synold T, Weiss L, Rahbar S. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab. Res. Rev., 21, 533-544 (2005).
14. Rahbar S, Kumar Yernini K, Scott S, Gonzales N, Lalezari I. Novel inhibitors of advanced glycation endproducts. Biochem. Biophys. Res. Commun., 262, 651-656 (1999).
15. Rahbar S, Yerneni KK, Scott S, Gonzales N, Lalezari I. Novel inhibitors of advanced glycation endproducts (Part II). Mol. Cell Biol. Res. Commun., 3, 360-366 (2000).
16. Wu CH, Yen GC. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. J. Agric. Food Chem., 53, 3167-3173 (2005).
17. Peng X, Cheng KW, Ma J, Chen B, Ho CT, Lo C, Chen F, Wang M. Cinnamon bark proanthocyanidins as reactive carbonyl scavengers to prevent the formation of advanced glycation endproducts. J. Agric. Food Chem., 56, 1907-1911 (2008).
18. Zhu H, Wang Z, Ma C, Tian J, Fu F, Li C, Guo D, Roeder E, Liu K. Neuroprotective effects of hydroxysafflor yellow A: in vivo and in vitro studies. Planta Med., 69, 429-433 (2003).
19. Wei X, Liu H, Sun X, Fu F, Zhang X, Wang J, An J, Ding H. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci. Lett., 386, 58-62 (2005).
20. Sun CY, Pei CQ, Zang BX, Wang L, Jin M. The ability of hydroxysafflor yellow a to attenuate lipopolysaccharide-induced pulmonary inflammatory injury in mice. Phytother. Res., 24, 1788-1795 (2010).
21. Zhang Y, Guo J, Dong H, Zhao X, Zhou L, Li X, Liu J, Niu Y. Hydroxysafflor yellow A protects against chronic carbon tetrachloride-induced liver fibrosis. Eur. J. Pharmacol., 660, 438-444 (2011).
22. Bie XD, Han J, Dai HB. Effects of hydroxysafflor yellow A on the experimental traumatic brain injury in rats. J. Asian Nat. Prod. Res., 12, 239-247 (2010).
23. Lee C, Yim MB, Chock PB, Yim HS, Kang SO. Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation. J. Biol. Chem., 273, 25272-25278 (1998).
24. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J., 344, 109-116 (1999).
25. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care, 5, 561-568 (2002).
26. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation end-products. Arch. Biochem. Biophys., 419, 63-79 (2003).
27. Fan L, Dang X, Shi Z, Zhang C, Wang K. Hydroxysafflor yellow A protects PC12 cells against the apoptosis induced by oxygen and glucose deprivation. Cell. Mol. Neurobiol., 31, 1187-1194 (2011).
28. Tian J, Li G, Liu Z, Fu F. Hydroxysafflor yellow A inhibits rat brain mitochondrial permeability transition pores by a free radical scavenging action. Pharmacology, 82, 121-126 (2008).